BEI Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Preliminary Phase III results for firm's Hydro ThermAblator (HTA) system in treating excessive uterine bleeding indicate that over 80% of 166 women experienced reduction in uterine bleeding, firm reports Sept. 6. BEI plans to submit results as the final part of its PMA approval application in mid-September. The firm already has filed three PMA modules with the agency (1"The Gray Sheet" Aug. 21, 2000, p. 13). The company also notes that the HTA completely eradicated menstrual bleeding in approximately 40% of treated patients
You may also be interested in...
Gynecologists Likely To Have New Options For Treating Menorrhagia In 2001
BEI Medical Systems' Hydro ThermAblator (HTA) system for endometrial ablation will provide a new option for gynecologists in the treatment of menorrhagia when it becomes available, likely in early 2001.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.